ARCC Investigator and Professor at the University of British Columbia, Dr. Michael M. Burgess will share his research on why deliberative public engagement is best used when the scale and urgency of policy decisions justify the expense and effort. Dr. Burgess is the next speaker in lecture series hosted by CADTH which is scheduled on Tuesday, December 8th, 2015 at 1 p.m. (EST).
Deliberative public engagement is expensive, labour-intensive, and produces knowledge that is limited in scope and extensibility. That said, if decisions about drugs are to be informed by diverse public perspectives, with citizens considering how they would balance fair decision-making with persistent substantive disagreement, then deliberative engagement is the only approach to consider.
For more information about this lecture, please CLICK HERE!
About CADTH Lecture:
CADTH hosts a series of lectures by prominent scholars and opinion leaders to share their perspectives on some of the most pressing issues facing health technology assessment (HTA) in the present time.
About Dr. Michael M. Burgess
Michael M. Burgess is Professor and Research Chair in Biomedical Ethics at the W. Maurice Young Centre for Applied Ethics in the Department of Medical Genetics at the University of British Columbia. His research has focused on health, science and technology policy and public engagement based on theories of deliberative democracy. With co-lead Kieran O’Doherty, the research team developed an approach to deliberative engagement on biotechnology policy, with eight events in BC, the Mayo Clinic and in western Australia across topics of biobanks, salmon genomics and environmental remediation. Recently, Dr. Burgess has begun to emphasize the wider social effects and policy implications of genomic and computational technologies often characterized as personalized medicine.